X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Sputnik Light is a single-dose vaccine and the same as the first component -- recombinant human adenovirus serotype number 26 (rAd26) -- of the two-dose Sputnik V vaccine.
Lead Product(s): rAd26
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik Light
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: Dr. Reddy\'s Laboratories
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2022
Details:
Sputnik V and Sputnik Light are based on a safe and effective human adenoviral vector platform and have not been associated with rare serious adverse events following vaccination, such as myocarditis or pericarditis.
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2022
Details:
Sputnik V (Gam-COVID-Vac), shows significantly smaller (2.6 times) reduction of virus-neutralizing activity against Omicron as compared to the reference Wuhan variant than Pfizer vaccine (8.1-fold reduction for Sputnik V in contrast to 21.4-fold reduction for Pfizer vaccine).
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: The Gamaleya National Center of Epidemiology and Microbiology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2022
Details:
Sputnik Light (rAd26) vaccine demonstrates 91.6% efficacy rate against coronavirus, the world’s first registered vaccine against the novel coronavirus infection, is now approved for use in over 50 countries.
Lead Product(s): rAd26
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik Light
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: Stelis Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2021
Details:
Cambodia has become the 71st country in the world to register the Russian vaccine. Sputnik V was granted an emergency use authorization. The one-shot Sputnik Light vaccine is based on the human adenovirus serotype 26, the first component of Sputnik V.
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2021
Details:
Sputnik V's efficacy against infection with the Delta variant is 83% and 94% against hospitalization. To date Sputnik V has been registered in 70 countries in various parts of the world with total population of over 4 billion people.
Lead Product(s): ChAdOx1 nCoV-19,rAd26-S
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2021
Details:
Preliminary results show combination of vaccine cocktail of AstraZeneca's ChAdOx1 nCoV-19 vaccine (AZD1222) and Sputnik Light vaccines demonstrate high immunogenicity profile in clinical study and high safety profile with no serious adverse events.
Lead Product(s): ChAdOx1 nCoV-19,rAd26-S
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2021
Details:
According to the study in the Province of Buenos Aires, the first component of Sputnik V (Sputnik Light) has shown 78.6-83.7% efficacy against COVID-19 in high-risk elderly subjects which is significantly higher than efficacy demonstrated by most two-component vaccines.
Lead Product(s): rAd26
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik Light
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2021
Details:
The efficacy of Sputnik V was measured based on the monitoring of COVID cases between 25 February and 23 August, 2021. Sputnik V is the most efficient vaccine against hospitalizations with COVID-19 in the country.
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2021
Details:
The Sputnik Light vaccine is based on a well-studied human adenoviral vector platform that has proven to be safe and effective, with no long-term side effects, as confirmed in over 250 clinical trials conducted globally over the past two decades .
Lead Product(s): ChAdOx1 nCoV-19,Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
